Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A real-world study found that patients with chronic spontaneous urticaria (CSU) treated with omalizumab had significantly lower rates of cardiovascular disease compared to those on oral corticosteroids or antihistamines. Within 3 years, only 3.55% of omalizumab-treated patients developed CVD vs. 8.06% on oral corticosteroids. Researchers caution this doesn't prove a direct heart-protective effect of the drug.
A new retrospective study suggests that omalizumab, a biologic commonly used to treat chronic spontaneous urticaria (CSU), is associated with a meaningfully lower risk of cardiovascular disease (CVD) compared to oral corticosteroids and second-generation antihistamines. The findings, published in Clinical and Translational Allergy, analyzed real-world data from over 3,300 patients per treatment group using the US TriNetX Collaborative Network.
The results revealed a clear hierarchy: omalizumab users had the lowest CVD risk, followed by antihistamine users, with oral corticosteroid users faring worst. The association held across multiple follow-up windows and sensitivity analyses, suggesting the pattern is robust — though researchers stress it doesn't confirm a direct cardioprotective mechanism.
By the Numbers:
Why it matters: These findings reinforce the importance of factoring CVD risk into CSU treatment decisions. While omalizumab's cardiovascular benefit may partly reflect differences in disease severity or monitoring, the data add another dimension to the case for biologic therapy in appropriate CSU patients.
